paxlovid是整体防疫的一部分
美国分配Paxlovid的演变
中国该如何分配Paxlovid?
1.https://www.nejm.org/doi/full/10.1056/NEJMoa2118542
2.https://www.nejm.org/doi/full/10.1056/NEJMoa2204919
3.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19
4.https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/
5.https://www.fiercepharma.com/pharma/jpm-2022-pfizer-bumps-paxlovid-production-estimate-to-120-million-for-year-while-also
6.https://www.covid19treatmentguidelines.nih.gov/overview/prioritization-of-therapeutics/
7.https://aspr.hhs.gov/TestToTreat/Pages/default.aspx
8.https://aspr.hhs.gov/COVID-19/Therapeutics/Orders/Pages/default.aspx
2024-09-02
2024-09-04
2024-09-23
2024-08-28
2024-09-27
2024-08-27
2024-09-09
近年来,RNA疗法及其在疾病治疗中的潜力备受关注,今年诺贝尔生理学或医学奖授予微小RNA(microRNA)领域的研究更是将这一热度推向高峰。在新药研发蓬勃发展的今天,小核酸药物被视为继小分子药和抗体药之后的“第三次制药浪潮”的关键力量。
作者:崔芳菲
评论
加载更多